VISTAGEN THERAPEUTICS, INC. Capital Expenditures
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Capital Expenditures of $212.00 thousand for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2023-02-07
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $12.50K.
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $24.40K, a 51.68% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-06-30 was $175.10K, a 16.81% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-03-31 was $100.00, a 99.61% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $200.40K, a 27.23% decline from fiscal 2021.
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $275.40K.
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- VISTAGEN THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2019 was $174.00K, a 10775.00% increase from fiscal 2018.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2022-12-31 | $12.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-07 | $36.90K derived: sum of 2 quarters · filed 2023-02-07 | $212.00K 10-Q · filed 2023-02-07 | $212.10K derived: sum of 4 quarters · filed 2023-02-07 |
| 2022-09-30 | $24.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-10 | $199.50K 10-Q · filed 2022-11-10 | $199.60K derived: sum of 3 quarters · filed 2022-11-10 | $199.50K derived: sum of 4 quarters · filed 2023-02-07 |
| 2022-06-30 | $175.10K 10-Q · filed 2022-08-11 | $175.20K derived: sum of 2 quarters · filed 2022-08-11 | $175.10K derived: sum of 3 quarters · filed 2023-02-07 | $225.60K derived: sum of 4 quarters · filed 2023-02-07 |
| 2022-03-31 | $100.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-07 | $50.50K derived: sum of 3 quarters · filed 2023-02-07 | $200.40K 10-K · filed 2022-06-23 |
| 2021-12-31 | -$100.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-07 | $50.40K derived: sum of 2 quarters · filed 2023-02-07 | $200.30K 10-Q · filed 2023-02-07 | $225.80K derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-09-30 | $50.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-10 | $200.40K 10-Q · filed 2022-11-10 | $200.40K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $149.90K 10-Q · filed 2022-08-11 | $175.40K derived: sum of 2 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $25.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $275.40K 10-K · filed 2022-06-23 | ||
| 2020-12-31 | $249.90K 10-Q · filed 2022-02-10 | |||
| 2020-09-30 | $98.80K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $0.00 10-K · filed 2021-06-29 | |||
| 2019-03-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29 | $174.00K derived: sum of 2 quarters · filed 2020-06-29 | $174.00K 10-K · filed 2020-06-29 | |
| 2018-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-12 | $0.00 10-Q · filed 2019-02-12 | ||
| 2018-09-30 | $0.00 10-Q · filed 2018-10-29 | |||
| 2018-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-25 | $3.20K derived: sum of 2 quarters · filed 2019-06-25 | $1.60K 10-K · filed 2019-06-25 | |
| 2017-12-31 | $3.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-12 | $1.60K 10-Q · filed 2019-02-12 | ||
| 2017-09-30 | -$1.60K 10-Q · filed 2018-10-29 | |||
| 2017-03-31 | $239.10K 10-K · filed 2018-06-26 | |||
| 2016-03-31 | $26.30K 10-K · filed 2017-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |